Skip to main content
. 2019 Mar 24;7(6):750–758. doi: 10.1177/2050640619841538

Figure 4.

Figure 4.

(a) VDZ TLs at week 2 according to wash-out periods. Median VDZ TLs at 22.8 µg/ml (IQR (17.1–33.2), n = 25) and 26.9 µg/ml (IQR (20.2–32.8), n = 29) for wash-out period <6 weeks and >6 weeks, respectively. (b) Residual IFX TLs at third infusion of VDZ (week 6) according to wash-out periods. Median residual IFX TL at 0.5 µg/ml (IQR (0–1.5), n = 19) and 0 µg/ml (IQR (0–0.5) n = 19) for wash-out period <6 weeks and >6 weeks, respectively. IFX: infliximab/CT-P13; IQR: interquartile range; TL: trough level; VDZ: vedolizumab; WO: wash-out.